

1 **Novel MAPK/AKT-impairing germline NRAS variant identified in a melanoma-prone**
2 **family**

3
4 Kevin M. Brown^{1*}, Mai Xu^{1*}, Michael Sargen¹, Hyunbum Jang², Mingzhen Zhang², Tongwu
5 Zhang¹, Bin Zhu¹, Kristie Jones¹, Jung Kim¹, Laura Mendoza¹, Nicholas K. Hayward³, Margaret
6 A. Tucker¹, Alisa M. Goldstein¹, Xiaohong Rose Yang¹, Douglas R. Stewart¹, Belynda Hicks¹,
7 Dario Consonni⁴, Angela C. Pesatori^{4,5}, Maria Concetta Fagnoli⁶, Ketty Peris⁷, Alex Stratigos⁸,
8 Chiara Menin⁹, Paola Ghiorzo¹⁰, Susana Puig¹¹, Eduardo Nagore¹², MelaNostrum Consortium[^],
9 Thorkell Andresson², Ruth Nussinov^{2,13}, Donato Calista¹⁴, Maria Teresa Landi¹

10

11 ¹ Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of
12 Health, Bethesda, MD USA

13 ² Computational Structural Biology Section, Frederick National Laboratory for Cancer Research,
14 Frederick MD USA

15 ³ Oncogenomics Laboratory, QIMR Berghofer Research Institute, Brisbane, Australia

16 ⁴ Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Occupational Health Unit,
17 Milan, Italy

18 ⁵ Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

19 ⁶ Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of
20 L'Aquila, L'Aquila, Italy

21 ⁷ Institute of Dermatology, Catholic University, Rome, Italy

22 ⁸ Department of Dermatology, Andreas Syggros Hospital, Medical School, National and
23 Kapodistrian University of Athens, Athens, Greece

24 ⁹ Immunology and Diagnostic Molecular Oncology Unit, Veneto Institute of Oncology IOV –
25 IRCCS, Padua, Italy

26 ¹⁰ IRCCS Ospedale Policlinico San Martino, Genetics of Rare Cancers, Genoa, Italy and
27 Department of Internal Medicine and Medical Specialties, University of Genoa, Italy

28 ¹¹ Dermatology Department, Melanoma Unit, Hospital Clínic de Barcelona, IDIBAPS,
29 Universitat de Barcelona, CIBERER, Barcelona, Spain

30 ¹² Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain

31 ¹³ Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel
32 Aviv University, Tel Aviv, Israel

33 ¹⁴ Department of Dermatology, Maurizio Bufalini Hospital, Cesena, Italy

34
35

36 *These authors contributed equally to this work.

37

38 Address correspondence to:

39 Maria Teresa Landi, MD, PhD

40 Senior Investigator

41 Division of Cancer Epidemiology and Genetics

42 National Cancer Institute, National Institutes of Health

43 9609 Medical Center Drive, EPS 7106

44 Bethesda, MD 20892

45 E-mail: landim@mail.nih.gov

46 Phone: 240-276-7236

47 Cell: 301-978-1406

48
49

50 ^ Membership of the MelaNostrum Consortium can be found here:

51 <https://dceg.cancer.gov/research/cancer-types/melanoma/melanostrum>

52
53

54 The authors declare no conflicts of interest and have no financial disclosures.

55 **Abstract**

56 While several high-penetrance melanoma risk genes are known, variation in these genes fail to
57 explain melanoma susceptibility in a large proportion of high-risk families. As part of a
58 melanoma family sequencing study, including 435 families from Mediterranean populations, we
59 identified a novel *NRAS* variant (c.170A>C, p.D57A) in a melanoma-prone family. This variant
60 is absent in exomes in gnomAD, ESP, UKBiobank, and the 1000 Genomes Project, as well as in
61 11 273 Mediterranean individuals and 109 melanoma-prone families from the US and Australia.
62 This variant occurs in the GTP-binding pocket of NRAS. Differently from other RAS activating
63 alterations, NRAS D57A expression is unable to activate MAPK-pathway both constitutively
64 and after stimulation but enhances EGF-induced PI3K-pathway signaling in serum starved
65 conditions *in vitro*. Consistent with *in vitro* data demonstrating that NRAS D57A does not enrich
66 GTP binding, molecular modeling suggests that the D57A substitution would be expected to
67 impair Mg²⁺ binding and decrease nucleotide-binding and GTPase activity of NRAS. While we
68 cannot firmly establish NRAS c.170A>C (p.D57A) as a melanoma susceptibility variant, further
69 investigation of *NRAS* as a familial melanoma gene is warranted.

70

71

72 **Introduction**

73 Melanoma incidence has been increasing in Australia, Europe, and the United States for several
74 decades. In 2018, there were 290 000 cases of melanoma worldwide, and approximately 5-10%
75 of cases occur in individuals with a family history of melanoma (1-4). Multiple melanoma-
76 predisposition genes (*CDKN2A*, *CDK4*, *BAP1*, *POT1*, *TERT*, *ACD*, *TERF2IP*) explain melanoma
77 susceptibility in 20-30% of melanoma-prone families, suggesting that inherited risk for most
78 families results from multiple moderate to low penetrance susceptibility genes or yet unidentified
79 high-penetrance susceptibility genes (5).

80
81 Somatic *NRAS* mutations are identified in approximately 20% of primary melanomas and occur
82 in tumors that are *BRAF* wild type (6). In contrast, germline variants of *NRAS* and other genes of
83 the *RAS* pathway predispose to syndromes including Noonan Syndrome (7). In this report we
84 describe a family with a novel germline variant of *NRAS* (c.170A>C, p.D57A) in which affected
85 carriers developed melanoma and autoimmunity.

86

87 **Results**

88 **Family clinical history**

89 The proband of the family (**Fig 1A, S1 Fig**) was diagnosed with an invasive cutaneous
90 melanoma of his right arm at age 35-39, which was successfully treated with wide local excision.
91 One year later, he was diagnosed with Sjogren's syndrome after serologies were ordered for
92 chronic xerophthalmia. His symptoms were successfully controlled with artificial tears and did
93 not require systemic treatment. At age 60-64, the patient was diagnosed with an oncocytoma in
94 his right kidney. Prior to this diagnosis, the patient denied any history of pneumothorax or prior

95 skin biopsies demonstrating fibrofolliculomas/trichodiscomas to suggest a diagnosis of Birt-
96 Hogg-Dubé (BHD) syndrome (OMIM: 135150). On clinical exam, the patient also did not
97 exhibit any white or pink papules on the face that would be consistent with
98 fibrofolliculomas/trichodiscomas.

99
100 The proband's mother had two melanomas, with the first diagnosis on the back at age 60-64 and
101 the second diagnosis on the face at age 65-69. She was also diagnosed with primary biliary
102 cholangitis as a young adult. The proband's maternal grandmother had anal cancer (reported by
103 the proband as possibly mucosal melanoma, but the diagnosis is unconfirmed), but no history of
104 autoimmune disease. The proband's father was diagnosed with liver cancer at age 65-69, which
105 was thought to be secondary to chronic HCV infection. The proband has two healthy children,
106 both without any history of autoimmune disease, melanoma, or other cancers; his son was
107 diagnosed with clinically dysplastic nevi (as was the proband). The family history was negative
108 for other malignancies. Syndromic features of RASopathies, including facial dysmorphism,
109 cardiac abnormalities, and skin findings (lentigines, hemangiomas), were not present in the
110 family.

111

112 **Genetics**

113 As part of a larger whole-exome sequencing (WES) study of 435 high-risk melanoma families
114 [675 affected individuals or obligate carriers sequenced] of Mediterranean ancestry (8), germline
115 sequencing of the proband and his mother revealed the presence of a shared novel variant in
116 *NRAS* [g.chr1:115256541T>G, NM_002524.4 c.170A>C, NP_002515.1 p.D57A]; both were
117 mutation-negative for known melanoma susceptibility genes (*CDKN2A*, *CDK4*, *BAP1*, *POT1*,

118 *TERT*, *ACD*, *TERF2IP*, and *MITF* E318K); the proband did not carry any pathogenic variants in
119 genes associated with oncocyoma (*FLCN*, *TSC1*, or *TSC2*) or monogenic autoimmune
120 syndromes. Sanger sequencing confirmed this variant in the proband, proband's mother, and
121 proband's unaffected brother (**Fig 1A and 1B**), with all individuals being heterozygous. No other
122 rare or novel *NRAS* variants were found in other melanoma families. This variant is classified as
123 likely pathogenic by InterVar (applying ClinGen RASopathy recommendation) (9) and predicted
124 deleterious by multiple *in-silico* prediction tools (REVEL=0.924, CADD=24.3,
125 metaSVM=damaging). The variant has not been observed in ClinVar or HGMD. In addition,
126 similar to somatic activating mutations found in melanomas and nevi (codons 12, 13, and 61)
127 (10, 11), or alternatively in the germline of families with a group of syndromic conditions
128 broadly termed rasopathies (codons 12, 13, 50, 58, and 60) (12), D57 is located in the RAS GTP-
129 binding pocket.

130
131 This variant has not been reported in gnomAD, ESP, UKBiobank, and 1000 Genomes Project
132 other germline codon 57 variants appear to be exceptionally rare, with only a single non-
133 synonymous codon 57 allele (1:g.115256542C>T, c.169G>A, p.D57N) found in gnomAD
134 (1/113 658 non-Finnish European alleles). While confirming the presence of the variant in DNA
135 from the proband and his mother (used as positive controls), TaqMan genotyping of samples
136 from the MelaNostrum Consortium (13, 14) (**S1 Table**) found this alteration to be altogether
137 absent in 5 184 alleles of the same national ancestry as the proband (including both melanoma
138 cases and healthy controls; hundreds of individuals were from the same area of the country from
139 which the family comes), as well as 12 958 additional alleles of Mediterranean ancestry (of
140 different countries as the proband). We also examined additional WES data generated from

141 participants of the EAGLE (15) study, with this variant absent in 4 404 alleles (1 371 lung cancer
142 cases and 831 healthy controls) as well in 308 melanoma cases from 109 high-risk melanoma
143 families from the US and Australia.

144

145 ***In vitro* characterization of NRAS D57A**

146 The D57 residue of NRAS is highly conserved in RAS orthologs and paralogs and located within
147 a guanine nucleotide-binding pocket (16). Nearby germline variants T50I and G60E of *NRAS*
148 have been reported in patients with Noonan Syndrome (7), and *in vitro* characterization showed
149 that these alterations enhanced stimulus-dependent MAPK activation, similar to several
150 somatically activating mutations previously identified in melanomas (G12V, Q61R). To explore
151 the possible functional consequences of the *NRAS* c.170A>C (D57A) variant, we expressed it in
152 COS7 cells, and its effect on MAPK and PI3K signaling pathway was compared with both wild-
153 type NRAS and the oncogenic NRAS G12V mutation. While NRAS G12V stimulated
154 constitutive activation of both ERK and AKT, as well as EGF-mediated activation of ERK and
155 AKT under serum-starved conditions, NRAS D57A specifically enhanced AKT but not ERK
156 phosphorylation only upon treatment of human EGF under serum starvation (**Fig 2A**).
157 Furthermore, enhanced AKT activation via NRAS D57A expression disappears with increased
158 dose of EGF, suggesting that this variant may function under sub-optimal growth conditions (**Fig**
159 **3**). In addition, D57A NRAS appeared to be deficient in activation of MAPK signaling even in
160 the presence of serum. As D57 is part of the guanine nucleotide-binding pocket and NRAS
161 function is regulated by its nucleotide binding status, we pulled down GTP-bound NRAS with
162 RAF1 RAS-binding domain-conjugated agarose beads. Unlike WT NRAS and NRAS G12V,
163 D57A NRAS was not enriched in the GTP-bound state (**Fig 2B**), seemingly contradictory to

164 enhanced AKT activation upon EGF treatment but consistent with the overall observed lack of
165 MAPK activation. Of note, we also consistently observed less expression of D57A NRAS than
166 either wild-type NRAS or G12V NRAS, and the NRAS D57A band migrates faster through gels
167 compared to its WT or G12V counterpart, perhaps suggesting altered protein stability and/or
168 post-translational modification.

169

170 **Molecular modeling of NRAS D57A protein**

171 *In vitro* data are consistent with molecular modeling of this variant. As most activating RAS
172 mutations activate both MAPK and AKT signaling pathways, NRAS D57A appears to be a
173 unique RAS variant that specifically activates the AKT pathway under low stimulus conditions.
174 Visualization of the RAS nucleotide-binding pocket by neutron crystallography indicates that
175 protonation of D57 will impair Mg^{2+} retention, thus decrease nucleotide-binding activity and
176 GTPase activity of RAS, making it less stable in structure (16). The D57A variant identified in
177 the melanoma family would be expected to have the same effect as protonation of D57 and as a
178 result, this variant may be predicted to affect its catalytic activity as well as protein stability.

179

180 To further characterize the biological effects of the D57A alteration, we used molecular
181 modeling to analyze the molecular behavior of NRAS D57A. We performed the 500 ns
182 simulations for both wild-type NRAS and NRAS D57A in the explicit solvent. D57 contributed
183 to the coordination of Mg^{2+} in NRAS, with a distance of $\sim 4.5\text{\AA}$. Upon D57A mutation, the
184 distance of A57 to Mg^{2+} is predicted to increase to $\sim 7.0\text{\AA}$ (**Fig 4A-4C**). This is consistent with
185 the molecular findings where D57A NRAS protein was not enriched for its GTP-bound state. In
186 NRAS, D57 interacts with T35 (switch I region) via hydrogen bonds and coordinates the Mg^{2+}

187 ion along with S17. In simulations, the D57A variant disrupted the local residue contacts,
188 increasing the side chain distances (**Fig 4D-4E**). These changes in the local residue contacts by
189 the D57A mutation induce a conformational change of switch I region. The side chain of Y32
190 reorients towards the GTP's γ -phosphate, with the distance decreased (**Fig 4F**). Notably, D57A
191 NRAS affects the PI3K/AKT pathway but is seemingly deficient in MAPK-pathway activation
192 *in vitro* relative to wild-type NRAS (**Fig 2A**). A previous study investigating the effects of man-
193 made mutations to the GTP-binding pocket of HRAS observed that D57A decreases binding to
194 CRAF *in vitro* (17). RAS interacts with the RBD of RAF in the MAPK pathway mainly through
195 the switch I region (18, 19), where both the switch I and II regions mediate the RAS interactions
196 with PI3K in the PI3K/AKT pathway (20). The conformational change of switch I upon D57A
197 mutation is expected to affect the RAF interactions. In sum, the D57A substitution is predicted to
198 impair Mg^{2+} retention, decrease nucleotide-binding and GTPase activity of RAS, and likely
199 making it less stable in structure (16), suggesting NRAS D57A is a functional variant enhancing
200 AKT activation under some conditions, as well as potentially altering nucleotide binding activity
201 and protein structure.

202

203 **Discussion**

204 As part of a large melanoma family exome-sequencing study, we identified a novel germline
205 variant of *NRAS* (c.170A>C /p.D57A) in two melanoma cases from a melanoma family. This
206 variant has not been identified in any population to date (cataloged by gnomAD, 1000 Genomes
207 Project, ESP, and UKBiobank), we did not observe it in >22 000 Mediterranean alleles
208 (including >9 500 alleles from the same country as the proband) and in 109 melanoma-prone
209 families from the US and Australia, and germline alteration of *NRAS* codon 57 appears to be

210 exceedingly rare, with only one single mutant allele (D57N) cataloged by gnomAD. Further,
211 multiple *in-silico* prediction tools predict this variant to be pathogenic.

212

213 *In vitro* assays and molecular modeling suggest that this variant, located within the GTP-binding
214 pocket of NRAS where other recurrent functional germline and somatic variants cluster, clearly
215 alters NRAS function. Notably, while well-characterized germline and somatic variants of RAS
216 proteins most often result in activation of either both PI3K and MAPK, *in vitro* assays
217 demonstrate D57A did not activate MAPK in the presence of serum and enhanced only AKT
218 phosphorylation via EGF under serum starvation, making this subtly-activating variation unique.
219 Consistent with these findings, the corresponding mutation in HRAS has been previously shown
220 to result in decreased binding of HRAS to CRAF (17) *in vitro*. Our *in vitro* assays additionally
221 suggest D57A may result in altered protein stability and or post-translational modification, and
222 molecular modeling suggests this mutation is likely to alter Mg²⁺ retention and decrease
223 nucleotide-binding activity and GTPase activity.

224

225 Given the small size of this family, it is difficult to assess the impact of this alteration on
226 melanoma and/or autoimmune syndrome risk, as (1) we do not observe *NRAS* variation in other
227 melanoma families, (2) observed cosegregation with melanoma may be due to chance, (3) we
228 observe this variant in the proband's sibling who has been unaffected to date, and (4) no
229 germline material is available from other members of this family diagnosed with melanoma or
230 with autoimmune symptoms, nor are tissues from the proband or his mother.

231

232 In conclusion, we identified a novel, functionally significant germline variant of *NRAS* in a
233 melanoma-prone family. While a direct association with melanoma risk cannot be firmly
234 established from this observation, investigation of *NRAS* variants potentially harbored by other
235 melanoma-prone families including those drawn from other populations, is warranted. The
236 proband was also diagnosed with both Sjogren's syndrome and oncocytoma; further
237 investigation of families with autoimmune diseases and/or kidney tumors may shed additional
238 light on whether this mutation may influence risk of these diseases.

239

240 **Materials and Methods**

241 **Whole exome sequencing of melanoma families**

242 675 melanoma cases or obligate carriers from 435 multi-case *CDKN2A/CDK4* mutation-negative
243 melanoma families (2-5 affected relatives) of Mediterranean ancestry from the MelaNostrum
244 Consortium (<https://dceg.cancer.gov/research/cancer-types/melanoma/melanostrum>) (14) were
245 whole-exome sequenced as a part of previously-published study for variant discovery (8).
246 Sequencing was performed using NimbleGen's SeqCap EZ Human Exome Library v2.0 or v3.0
247 (Roche NimbleGen, Inc., Madison, WI, USA) and an Illumina HiSeq (Illumina, Inc., San Diego,
248 CA, USA); sequencing, alignment and variant calling was performed as described previously (8).
249 Variants and population frequencies were annotated using ANNOVAR (21) and InterVar
250 (python version 2.1.2 20180603) (22). US melanoma families were exome-sequenced in the
251 same manner, while Australian families were exome-sequenced as previously described (23).
252 This overall study was approved by IRB at the National Cancer Institute, as well as local
253 institutions. All subjects provided written informed consent.

254

255 **Variant confirmation and genotyping in the population of the same country as the proband**

256 The presence of *NRAS* c.170A>C (p.D57A) in family members was confirmed via Sanger
257 sequencing using primers (F:5'-ACACCCCCAGGATTCTTACAG-3'; R: 5'-
258 GATTCAGAACACAAAGATCATCC-3') flanking the A170C region of *NRAS* coding
259 sequences. Genomic DNA of the family members were generated from whole blood. Sequencing
260 was performed on an ABI 3730xs DNA sequencer and sequence traces were analyzed using
261 Sequencher. Frequency of *NRAS* c.170A>C (p.D57A) in 6 154 melanoma cases and 2 917
262 healthy controls from the Melanostrum Consortium (13, 14) (**S1 Table**) was assessed using a
263 custom TaqMan genotyping assay with DNAs from two heterozygous carriers on every assay
264 plate as positive controls. Genotyping was performed using the following primers and probes
265 (primers: F:5'-TCTCTCATGGCACTGTACTCTTCT-3', R:5'-
266 TGGTTATAGATGGTGAAACCTGTTTGT; probes: 5'-FAM-CCAGCTGTAGCCAGTAT-3',
267 5'-VIC-TGTCCAGCTGTATCCAGTAT-3'). Genotyping was performed using 5 uL reaction
268 volumes consisting of: 2.5 uL of 2X KAPA Probe Fast MasterMix (Kapa Biosystems, Woburn,
269 MA), 0.25 uL of 20X TaqMan® assay-specific mix of primers and probes, and 2.25 uL of MBG
270 Water. PCR was performed using 9700 Thermal Cycler (ThermoFisher, Waltham, MA, USA)
271 with the following conditions: 95°C hold for 3 min, 40 cycles of 95°C for 3 sec and 62°C for 30
272 sec, and 10°C hold. Endpoint reads were evaluated using the 7900HT Sequence Detection
273 System (ThermoFisher). We also assessed the frequency of *NRAS* c.170A>C (p.D57A) using
274 additional germline exome sequencing data (sequenced as described above) from 1 371 lung
275 cancer cases and 831 healthy controls from the Environment and Genetics in Lung Cancer
276 Etiology study (EAGLE; <https://eagle.cancer.gov>) (15).

277

278 **NRAS expression constructs**

279 An *NRAS* cDNA clone was purchased from Origene (Cat# RC202681), the C-terminal Myc-
280 DDK tag was removed and replaced with a stop codon immediately following the *NRAS* coding
281 sequence via PCR. p.G12V (c. 35G>T) and p.D57A (c. 170A>C) mutations were introduced
282 using a PCR-based site-directed mutagenesis protocol as described (Agilent Technologies, Cat
283 #200522-5). The sequences of all constructs were verified via Sanger sequencing.

284

285 *Cell culture, transfection, EGF stimulation, GST pull down, and western blotting*

286 COS-7 (ATCC CRL-1651) and 293FT (ThermoFisher Scientific R7007) cells were cultured in
287 DMEM medium (Quality Biologicals) containing 10% FBS. Where indicated, cells were treated
288 with recombinant human EGF protein (R&D, Cat# 236-EG-200) in medium free of FBS. *NRAS*
289 constructs (wild-type, p.G12V (c.G35T), and p.D57A (c.A170C) were transfected into COS7
290 cells using PolyFect Transfection reagent (Qiagen, Cat# 301105) while the transfection of 293FT
291 cells was performed using Lipofectamine 2000 from Invitrogen. Two days after transfection,
292 total cell lysates were generated in RIPA buffer (Thermo Scientific) and subjected to water bath
293 sonication (Bioruptor) Samples were resolved in NuPage 4-12% Bis-Tris gel (Invitrogen)
294 electrophoresis. The primary antibodies used were mouse anti- β -actin (Sigma, A5316), mouse
295 anti-Pan AKT (cell signaling, 2920S), rabbit anti-Phospho AKT(S473) (cell signaling, 4060S),
296 rabbit anti-total ERK1/2 (cell signaling, 9106S), mouse anti-Phospho ERK1/2 (Cell signaling,
297 4695S), and mouse anti-RAS (Millipore Cat# 05-516). To determine GTP-bound *NRAS* level in
298 cells expressing WT or mutant *NRAS* proteins, RAS-GTP was pulled down by RAF1-RBD
299 conjugated agarose beads followed by western by anti-RAS antibody (Millipore, Cat17-218).

300

301 **Molecular modeling**

302 The coordinates of wild-type GTP-bound NRAS were generated based on the structure of H-
303 RAS with residue modifications (24). The wild-type GTP-bound NRAS was mutated at D57A to
304 understand the mutational effect. The wild-type and GTP-bound NRAS D57A proteins were
305 solvated in the explicit-solvent solvent box of $\sim 69 \times 69 \times 69 \text{ \AA}^3$. Ions (Na^+ and Cl^-) were used to
306 neutralize and generate the 0.15M ionic strength in the system. Molecular dynamics (MD)
307 simulations were performed by the NAMD package with the updated CHARMM all-atom
308 additive force field (version C36) (25, 26). The simulations used the NPT (constant number of
309 atoms, pressure, and temperature) ensemble at a temperature of 310 K and pressure of 1 atm.
310 Short-range van der Waals (VdW) interactions were calculated by the switch function and the
311 long-range electrostatic interactions were calculated by Particle mesh Ewald (PME) method. 500
312 ns simulations were individually performed for wild-type and mutated NRAS with a time step of
313 2 fs. Analysis was performed using CHARMM, VMD tools and scripts.

314

315 **Acknowledgements**

316 This research was supported [in part] by the Intramural Research Program of the NIH, National
317 Cancer Institute, Division of Cancer Epidemiology and Genetics (ZIACP010201 for KMB,
318 ZIACP010231 for MTL, and ZIACP010144 for MS; <https://dceg.cancer.gov/>) and Center for
319 Cancer Research (ZIABC010442 for RN; <https://ccr.cancer.gov/>) and the National Health and
320 Medical Research Council of Australia (1117663 for NKH; <https://www.nhmrc.gov.au>). This
321 project has been funded in whole or in part with federal funds from the National Cancer Institute,
322 National Institutes of Health, under contract HHSN26120080001E. The content of this
323 publication does not necessarily reflect the views or policies of the Department of Health and

324 Human Services, nor does mention of trade names, commercial products, or organizations imply
325 endorsement by the U.S. Government. Funders had no role in study design, data collection and
326 analysis, decision to publish, or preparation of the manuscript. All simulations were performed
327 using the high-performance computational facilities of the Biowulf PC/Linux cluster at the
328 National Institutes of Health, Bethesda, MD (<https://hpc.nih.gov/>). Membership of the
329 Melanostrum Consortium can be found at the following link:
330 <https://dceg.cancer.gov/research/cancer-types/melanoma/melanostrum>

331 **References**

- 332 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer
333 statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in
334 185 countries. *CA Cancer J Clin.* 2018;68(6):394-424.
- 335 2. Florell SR, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G, et al. Population-
336 based analysis of prognostic factors and survival in familial melanoma. *J Clin Oncol.*
337 2005;23(28):7168-77.
- 338 3. Glazer AM, Winkelmann RR, Farberg AS, Rigel DS. Analysis of Trends in US
339 Melanoma Incidence and Mortality. *JAMA Dermatol.* 2017;153(2):225-6.
- 340 4. Whiteman DC, Green AC, Olsen CM. The Growing Burden of Invasive Melanoma:
341 Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations
342 through 2031. *J Invest Dermatol.* 2016;136(6):1161-71.
- 343 5. Potrony M, Badenas C, Aguilera P, Puig-Butille JA, Carrera C, Malveyh J, et al. Update
344 in genetic susceptibility in melanoma. *Ann Transl Med.* 2015;3(15):210.
- 345 6. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, et al.
346 BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with
347 melanoma. *J Clin Oncol.* 2012;30(20):2522-9.
- 348 7. Cirstea IC, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D, et al. A restricted
349 spectrum of NRAS mutations causes Noonan syndrome. *Nat Genet.* 2010;42(1):27-9.
- 350 8. Shi J, Yang XR, Ballew B, Rotunno M, Calista D, Fargnoli MC, et al. Rare missense
351 variants in POT1 predispose to familial cutaneous malignant melanoma. *Nat Genet.*
352 2014;46(5):482-6.
- 353 9. Gelb BD, Cave H, Dillon MW, Gripp KW, Lee JA, Mason-Suares H, et al. ClinGen's
354 RASopathy Expert Panel consensus methods for variant interpretation. *Genet Med.*
355 2018;20(11):1334-45.
- 356 10. Burd CE, Liu W, Huynh MV, Waqas MA, Gillahan JE, Clark KS, et al. Mutation-
357 specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. *Cancer Discov.*
358 2014;4(12):1418-29.
- 359 11. Jakob JA, Bassett RL, Jr., Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS
360 mutation status is an independent prognostic factor in metastatic melanoma. *Cancer.*
361 2012;118(16):4014-23.

- 362 12. Martinelli S, Stellacci E, Pannone L, D'Agostino D, Consoli F, Lissewski C, et al.
363 Molecular Diversity and Associated Phenotypic Spectrum of Germline CBL Mutations. *Hum*
364 *Mutat.* 2015;36(8):787-96.
- 365 13. Landi MT, Bishop DT, MacGregor S, Machiela MJ, Stratigos AJ, Ghiorzo P, et al.
366 Genome-wide association meta-analyses combining multiple risk phenotypes provide insights
367 into the genetic architecture of cutaneous melanoma susceptibility. *Nat Genet.* 2020;52(5):494-
368 504.
- 369 14. Stratigos AJ, Fagnoli MC, De Nicolo A, Peris K, Puig S, Soura E, et al. MelaNostrum: a
370 consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk
371 assessment by the melanostrum consortium. *J Eur Acad Dermatol Venereol.* 2018;32(12):2134-
372 41.
- 373 15. Landi MT, Consonni D, Rotunno M, Bergen AW, Goldstein AM, Lubin JH, et al.
374 Environment And Genetics in Lung cancer Etiology (EAGLE) study: an integrative population-
375 based case-control study of lung cancer. *BMC Public Health.* 2008;8:203.
- 376 16. Knihtila R, Holzapfel G, Weiss K, Meilleur F, Mattos C. Neutron Crystal Structure of
377 RAS GTPase Puts in Question the Protonation State of the GTP gamma-Phosphate. *J Biol Chem.*
378 2015;290(52):31025-36.
- 379 17. Shirouzu M, Koide H, Fujita-Yoshigaki J, Oshio H, Toyama Y, Yamasaki K, et al.
380 Mutations that abolish the ability of Ha-Ras to associate with Raf-1. *Oncogene.* 1994;9(8):2153-
381 7.
- 382 18. Nussinov R, Tsai CJ, Muratcioglu S, Jang H, Gursoy A, Keskin O. Principles of K-Ras
383 effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle
384 deregulation. *Expert Rev Proteomics.* 2015;12(6):669-82.
- 385 19. Nussinov R, Zhang M, Tsai CJ, Liao TJ, Fushman D, Jang H. Autoinhibition in Ras
386 effectors Raf, PI3Kalpha, and RASSF5: a comprehensive review underscoring the challenges in
387 pharmacological intervention. *Biophys Rev.* 2018;10(5):1263-82.
- 388 20. Zhang M, Jang H, Nussinov R. The structural basis for Ras activation of PI3Kalpha lipid
389 kinase. *Phys Chem Chem Phys.* 2019;21(22):12021-8.
- 390 21. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants
391 from high-throughput sequencing data. *Nucleic Acids Res.* 2010;38(16):e164.
- 392 22. Li Q, Wang K. InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-
393 AMP Guidelines. *Am J Hum Genet.* 2017;100(2):267-80.

- 394 23. Robles-Espinoza CD, Harland M, Ramsay AJ, Aoude LG, Quesada V, Ding Z, et al.
395 POT1 loss-of-function variants predispose to familial melanoma. *Nat Genet.* 2014;46(5):478-81.
- 396 24. Jang H, Muratcioglu S, Gursoy A, Keskin O, Nussinov R. Membrane-associated Ras
397 dimers are isoform-specific: K-Ras dimers differ from H-Ras dimers. *Biochem J.*
398 2016;473(12):1719-32.
- 399 25. Brooks BR, Brooks CL, 3rd, Mackerell AD, Jr., Nilsson L, Petrella RJ, Roux B, et al.
400 CHARMM: the biomolecular simulation program. *J Comput Chem.* 2009;30(10):1545-614.
- 401 26. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, et al. Scalable
402 molecular dynamics with NAMD. *J Comput Chem.* 2005;26(16):1781-802.
403
- 404

405 **Figure Legends**

406

407 **Fig 1. Pedigree of melanoma family carrying *NRAS* c.170A>C (p.D57A).** (A) Pedigree of the
408 immediate family harboring *NRAS* c.170A>C (p.D57A) annotated with sequencing and
409 genotyping results. Individuals diagnosed with melanoma, other cancers, and dysplastic nevi are
410 annotated, and the proband is denoted with an arrow. (B) Sanger sequencing traces of
411 c.170A>C/p.D57A variant for familial carriers.

412

413 **Fig 2. *NRAS* D57A increases AKT signaling after EGF stimulation in serum-starved cells.**
414 (A) wild-type *NRAS*, as well as G12V and D57A *NRAS* variant were transiently transfected into
415 COS7 cells and were switched to serum-free medium at 24hrs after transfection, followed by
416 EGF treatment (10 ng/mL, 1m) after one day of serum starvation. Pan- and phospho-ERK and -
417 AKT were assessed by western blot. (B) WT *NRAS*, as well as G12V and D57A *NRAS*
418 mutations were transiently transfected in 293FT cells, and at day 2 after transfection, whole cell
419 extract was taken to pull down GTP-bound *NRAS* by RAF1_RBD conjugated agarose beads,
420 followed by western blotting. Left Panel: *NRAS* blot after pull-down; Right Panel: *NRAS* blot
421 before pull-down.

422

423 **Fig 3. *NRAS*^{D57A} effect on AKT signaling depends on EGF dose.** Constructs expressing wild-
424 type *NRAS*, as well as G12V and D57A *NRAS* mutations were transiently transfected into
425 COS7 cells and were switched to serum-free medium at 24hrs after transfection, followed by
426 EGF treatment (5, 10, and 20 ng/mL for 1 minute) after one day of serum starvation. Pan- and
427 phospho-ERK and -AKT were assessed by western blot.

428

429 **Fig 4. Structural insight into *NRAS*^{D57A}.** (A) The sequence of *NRAS* with select mutations
430 highlighted (T50I and G60E for Noonan Syndrome, and D57A for melanoma). (B) The
431 representative snapshots of wild-type *NRAS* and (C) *NRAS*^{D57A} from molecular dynamics (MD)
432 simulations. Upon D57A mutation, the interactions of D57 with (D) S17 and (E) T35 are
433 disrupted, with the distances increased. The side chain of Y32 reorients towards GTP with (F)
434 the distance decreased, suggesting a conformational change of switch I region upon D57A
435 mutation.

436

437 **Supplementary information**


438

439 **S1 Fig. Pedigree of the extended family harboring *NRAS*^{D57A} annotated with sequencing**
440 **and genotyping results.** Individuals diagnosed with melanoma, other cancers, and dysplastic
441 nevi are annotated, and the proband is noted with an arrow.


442

443 **S1 Table. MelaNostrum Consortium samples genotyped via TaqMan for *NRAS***
444 **p.D57A/c.A170C.**


A



B



A



B

